📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. (2023)

First Author: Goddard J

Attributed to: Anticipatory medicine: Can we identify, predict, and target mechanisms of disease relapse in childhood medulloblastoma? funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00401-023-02566-0

PubMed Identifier: 37014508

Publication URI: http://europepmc.org/abstract/MED/37014508

Type: Journal Article/Review

Volume: 145

Parent Publication: Acta neuropathologica

Issue: 5

ISSN: 0001-6322